icsm-dre-before-tt

Perform digital rectal examination (DRE) in all men before initiating testosterone therapy to exclude prostate abnormalities or support suspicion of hypogonadism when prostate volume is reduced. Trigg

SKILL.md

GitHub

Perform digital rectal examination before testosterone therapy

STEP 1 — Gather Information

Collect symptoms of hypogonadism (low libido, decreased morning erections, fatigue), confirm total testosterone <12 nmol/L on two separate morning fasting samples, and assess for contraindications to testosterone therapy.
Action: If symptomatic and biochemically confirmed hypogonadism, proceed to evaluate need for DRE; otherwise, do not initiate testosterone therapy.

STEP 2 — Rule In / Rule Out

Is the patient a candidate for testosterone therapy (symptomatic with confirmed low T)?

  • Yes: Proceed to DRE.
  • No: Do not start testosterone therapy; DRE not required.
    Decision: Based on the binary fork, either advance to DRE or withhold testosterone therapy.

STEP 3 — Classify or Stratify

After DRE, classify prostate findings: normal size, reduced size (suggestive of hypogonadism), enlarged benign (smooth, symmetrical), or suspicious (nodularity, hardness, asymmetry).
Action: If normal or reduced size, consider testosterone therapy; if enlarged benign, discuss risks and may proceed with monitoring; if suspicious, defer testosterone therapy and refer for urologic evaluation (PSA, biopsy).

STEP 4 — Decide

Based on DRE classification, decide to initiate testosterone therapy after shared decision‑making if the exam is non‑suspicious; otherwise, obtain PSA and refer to urology before considering testosterone therapy.
Decision: Start testosterone therapy with baseline PSA and plan for repeat DRE per monitoring schedule, or obtain further urologic work‑up if DRE is abnormal.

Clinical Guardrails / Mimics / Pitfalls

DRE does not exclude prostate cancer; PSA should be obtained per guidelines. Do not start testosterone therapy if DRE shows a suspicious nodule without further evaluation. DRE may miss anterior zone cancers. Ensure informed consent discussing benefits, risks, and monitoring requirements. Consider anticoagulation status before performing DRE.

Concrete Clinical Example

A 58‑year‑old man reports decreased libido and fatigue; total testosterone is 10 nmol/L on two occasions. Clinician performs DRE, finds a symmetrically enlarged prostate without nodules. After discussing risks and benefits, testosterone therapy is initiated with a baseline PSA and a plan for repeat DRE at 6 months.

Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, DOI: 10.1093/sxmrev/qeaf036